Point Of Care Poc Influenza Diagnostics Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The POC influenza diagnostics market sits inside the broader point-of-care testing industry, which is valued at approximately USD 44.7 billion in 2025 and projected to reach around USD 82 billion by 2034 at a 7% CAGR. Within infectious disease POC testing, estimated at USD 12-15 billion globally, influenza assays account for roughly an 8% revenue share. Demand is shaped by seasonal flu waves, pandemic preparedness programs, and the steady shift of diagnostic workflows out of central laboratories.

• •Parent POC testing market valued at ~USD 44.7 billion in 2025, expanding at ~7% CAGR
• •Infectious disease POC segment estimated at USD 12-15 billion, with influenza ~8% share
• •Forecast endpoint of ~USD 82 billion by 2034 for the overall POC testing sector

Rising prevalence of seasonal and pandemic influenza, alongside growing clinical emphasis on early antiviral intervention, is pushing healthcare providers toward rapid bedside testing. Decentralization of diagnostics into pharmacies, primary care, and home settings is expanding the addressable user base, while technological improvements in molecular POC platforms are improving sensitivity to levels approaching lab-based PCR. Reimbursement expansion for rapid infectious disease testing and government stockpiling programs further reinforce uptake.

• •Increasing respiratory disease burden and pandemic preparedness spending
• •Shift of testing from central labs to pharmacies, clinics, and home care
• •Molecular POC platforms now approaching lab-grade PCR sensitivity

The market is typically segmented by product type into rapid antigen tests and rapid molecular assays, with molecular tests capturing a growing premium-priced share. End users span hospitals, physician offices, urgent care, pharmacies, and home/self-testing, while distribution runs through both institutional procurement and retail pharmacy channels. North America leads revenue contribution due to high test volumes, established reimbursement, and strong seasonal flu surveillance, with Europe close behind and Asia-Pacific representing the fastest-growing region on the back of expanding healthcare access and outbreak preparedness investment.

• •Product split between rapid antigen assays and rapid molecular assays
• •North America leads revenue; Asia-Pacific is the fastest-growing regional market
• •End users include hospitals, urgent care, retail pharmacies, and home self-testing

What are the recent trends and outlook?

The next phase of growth is expected to come from multiplex POC panels that screen influenza alongside RSV, COVID-19, and other respiratory pathogens in a single sample. Integration with electronic health records, cloud-based surveillance dashboards, and AI-assisted result interpretation is moving POC devices closer to connected care ecosystems. Over the forecast horizon, the segment is likely to track the broader 7% CAGR of POC testing, with upside from pandemic preparedness funding and continued migration of molecular testing out of central laboratories.

• •Multiplex respiratory panels covering flu, RSV, and COVID-19 are a key growth vector
• •Connected POC platforms linking results to EHRs and public health surveillance
• •Pandemic preparedness funding and lab decentralization support above-market growth optionality